Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

knoll -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 17 jan 2005 : tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.,tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.

Kanada - angol - Health Canada

apotex inc - verapamil hydrochloride - tablet - 120mg - verapamil hydrochloride 120mg - miscellaneous calcium-channel blocking agents

Kanada - angol - Health Canada

sorres pharma inc - verapamil hydrochloride - tablet (extended-release) - 240mg - verapamil hydrochloride 240mg - miscellaneous calcium-channel blocking agents

Kanada - angol - Health Canada

janssen inc - darunavir (darunavir ethanolate) - tablet - 600mg - darunavir (darunavir ethanolate) 600mg - hiv protease inhibitors

Kanada - angol - Health Canada

janssen inc - darunavir (darunavir ethanolate) - tablet - 75mg - darunavir (darunavir ethanolate) 75mg - hiv protease inhibitors

Kanada - angol - Health Canada

janssen inc - darunavir (darunavir ethanolate) - tablet - 150mg - darunavir (darunavir ethanolate) 150mg - hiv protease inhibitors

Kanada - angol - Health Canada

janssen inc - darunavir (darunavir ethanolate); cobicistat - tablet - 800mg; 150mg - darunavir (darunavir ethanolate) 800mg; cobicistat 150mg - hiv protease inhibitors

Kanada - angol - Health Canada

abbvie corporation - ombitasvir; paritaprevir; ritonavir - tablet - 12.5mg; 75mg; 50mg - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg - hcv protease inhibitors

Egyesült Államok - angol - NLM (National Library of Medicine)

a-s medication solutions - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. coadminstration of atripla with voriconazole is contraindicated. efavirenz, a component of atripla, significantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole. also, voriconazole significantly increases efavirenz plasma concentrations, which may increase the risk of efavirenz-associated side effects. because atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered [see clinical pharmacology (12.3) tables 4 and 5]. pregnancy category d [see warnings and precautions (5.9)] antiret